Drug-pricing woes put the hurt on pharma junk bonds

Pharma's bonds are underperforming the wider junk-debt gauge, Bloomberg reports, with those sold by companies including Valeant ($VRX) and Endo ($ENDP) missing the mark. And that's bad news for drugmakers such as Concordia and Sucampo, which are marketing more than $2 billion of loans to finance takeovers. More

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.